Literature DB >> 26163475

Targeting HER (ERBB) signaling in head and neck cancer: An essential update.

Jun Zhang1, Nabil F Saba2, Georgia Zhuo Chen2, Dong M Shin3.   

Abstract

HNC (head and neck cancer) remains the 6th most common carcinoma worldwide. The suboptimal survival and toxicities observed with conventional approaches warrant exploration of novel therapeutic strategies such as targeted therapies. Although targeting EGFR (epidermal growth factor receptor) with cetuximab demonstrated clinical promise, HER (human epidermal growth factor receptor) or ERBB (erythroblastic leukemia viral oncogene homolog) targeted therapy in HNC has overall been suboptimal to date in clinical settings. Overcoming the resistance as well as identifying new strategies therefore remains a significant challenge. In this review, we will discuss the emerging roles of HER members besides EGFR. A comprehensive "three-dimensional" view of HER signaling pathway from the importance of EGFR nuclear translocation to our maturing concept of receptors' "spatial regulation", as well as the interdependence and interaction among different HER members will also be addressed to complete an essential update of HER signaling in HNC.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  EGFR; ERBB; HER; SCCHN; Targeted therapy

Mesh：

Substances：

Year:  2015        PMID： 26163475      PMCID： PMC8028037          DOI： 10.1016/j.mam.2015.07.001

Source DB:  PubMed          Journal:  Mol Aspects Med        ISSN： 0098-2997


  106 in total

1.  Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.

Authors:  Kaisa Erjala; Maria Sundvall; Teemu T Junttila; Na Zhang; Mika Savisalo; Pekka Mali; Jarmo Kulmala; Jaakko Pulkkinen; Reidar Grenman; Klaus Elenius
Journal:  Clin Cancer Res       Date:  2006-07-01       Impact factor: 12.531

2.  A subset of tumor-derived mutant forms of p53 down-regulate p63 and p73 through a direct interaction with the p53 core domain.

Authors:  C Gaiddon; M Lokshin; J Ahn; T Zhang; C Prives
Journal:  Mol Cell Biol       Date:  2001-03       Impact factor: 4.272

3.  Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial.

Authors:  Jan B Vermorken; Jan Stöhlmacher-Williams; Irina Davidenko; Lisa Licitra; Eric Winquist; Cristian Villanueva; Paolo Foa; Sylvie Rottey; Krzysztof Skladowski; Makoto Tahara; Vasant R Pai; Sandrine Faivre; Cesar R Blajman; Arlene A Forastiere; Brian N Stein; Kelly S Oliner; Zhiying Pan; Bruce A Bach
Journal:  Lancet Oncol       Date:  2013-06-06       Impact factor: 41.316

4.  Segregation of receptor and ligand regulates activation of epithelial growth factor receptor.

Authors:  Paola D Vermeer; Lisa A Einwalter; Thomas O Moninger; Tatiana Rokhlina; Jeffrey A Kern; Joseph Zabner; Michael J Welsh
Journal:  Nature       Date:  2003-03-20       Impact factor: 49.962

5.  Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines.

Authors:  Larry H Kalish; Rhonda A Kwong; Ian E Cole; Richard M Gallagher; Robert L Sutherland; Elizabeth A Musgrove
Journal:  Clin Cancer Res       Date:  2004-11-15       Impact factor: 12.531

6.  Blocking NRG1 and other ligand-mediated Her4 signaling enhances the magnitude and duration of the chemotherapeutic response of non-small cell lung cancer.

Authors:  Ganapati V Hegde; Cecile C de la Cruz; Cecilia Chiu; Navneet Alag; Gabriele Schaefer; Lisa Crocker; Sarajane Ross; David Goldenberg; Mark Merchant; Janet Tien; Lily Shao; Leslie Roth; Siao-Ping Tsai; Scott Stawicki; Zhaoyu Jin; Shelby K Wyatt; Richard A D Carano; Yanyan Zheng; E Alejandro Sweet-Cordero; Yan Wu; Erica L Jackson
Journal:  Sci Transl Med       Date:  2013-02-06       Impact factor: 17.956

7.  Nuclear EGFR contributes to acquired resistance to cetuximab.

Authors:  C Li; M Iida; E F Dunn; A J Ghia; D L Wheeler
Journal:  Oncogene       Date:  2009-08-17       Impact factor: 9.867

8.  Randomised Phase II study of oral lapatinib combined with chemoradiotherapy in patients with advanced squamous cell carcinoma of the head and neck: rationale for future randomised trials in human papilloma virus-negative disease.

Authors:  Kevin Harrington; Alain Berrier; Martin Robinson; Eva Remenar; Martin Housset; Fernando Hurtado de Mendoza; Jérôme Fayette; Hisham Mehanna; Iman El-Hariry; Natalie Compton; Natalie Franklin; Nigel Biswas-Baldwin; Mike Lau; Philippe Legenne; Rejnish Kumar
Journal:  Eur J Cancer       Date:  2012-12-19       Impact factor: 9.162

9.  Aurora kinase inhibition overcomes cetuximab resistance in squamous cell cancer of the head and neck.

Authors:  Alexander Hoellein; Anja Pickhard; Fabienne von Keitz; Stephanie Schoeffmann; Guido Piontek; Martina Rudelius; Anja Baumgart; Stefan Wagenpfeil; Christian Peschel; Tobias Dechow; Henning Bier; Ulrich Keller
Journal:  Oncotarget       Date:  2011-08

10.  High heregulin expression is associated with activated HER3 and may define an actionable biomarker in patients with squamous cell carcinomas of the head and neck.

Authors:  David S Shames; Juliet Carbon; Kim Walter; Adrian M Jubb; Cleopatra Kozlowski; Tom Januario; An Do; Ling Fu; Yuanyuan Xiao; Rajiv Raja; Brittany Jiang; Ashi Malekafzali; Howard Stern; Jeff Settleman; Timothy R Wilson; Garret M Hampton; Robert L Yauch; Andrea Pirzkall; Lukas C Amler
Journal:  PLoS One       Date:  2013-02-28       Impact factor: 3.240
View more
  10 in total

1.  HER3 Targeting Sensitizes HNSCC to Cetuximab by Reducing HER3 Activity and HER2/HER3 Dimerization: Evidence from Cell Line and Patient-Derived Xenograft Models.

Authors:  Dongsheng Wang; Guoqing Qian; Hongzheng Zhang; Kelly R Magliocca; Sreenivas Nannapaneni; A R M Ruhul Amin; Michael Rossi; Mihir Patel; Mark El-Deiry; J Trad Wadsworth; Zhengjia Chen; Fadlo R Khuri; Dong M Shin; Nabil F Saba; Zhuo G Chen
Journal:  Clin Cancer Res       Date:  2016-06-29       Impact factor: 12.531

2.  Glycosylation promotes the cancer regulator EGFR-ErbB2 heterodimer formation - molecular dynamics study.

Authors:  Zahra Motamedi; Hassan Rajabi-Maham; Maryam Azimzadeh Irani
Journal:  J Mol Model       Date:  2021-11-24       Impact factor: 1.810

Review 3.  HER3 in cancer: from the bench to the bedside.

Authors:  Lucía Gandullo-Sánchez; Alberto Ocaña; Atanasio Pandiella
Journal:  J Exp Clin Cancer Res       Date:  2022-10-21

4.  Targeting epidermal growth factor receptor for head and neck squamous cell carcinoma: still lost in translation?

Authors:  Christopher H Chapman; Nabil F Saba; Sue S Yom
Journal:  Ann Transl Med       Date:  2016-02

5.  AXL regulates neuregulin1 expression leading to cetuximab resistance in head and neck cancer.

Authors:  Mari Iida; Nellie K McDaniel; Kourtney L Kostecki; Noah B Welke; Carlene A Kranjac; Peng Liu; Colin Longhurst; Justine Y Bruce; Seungpyo Hong; Ravi Salgia; Deric L Wheeler
Journal:  BMC Cancer       Date:  2022-04-23       Impact factor: 4.638

Review 6.  The Role of Hormones and Trophic Factors as Components of Preservation Solutions in Protection of Renal Function before Transplantation: A Review of the Literature.

Authors:  Aneta Ostróżka-Cieślik; Barbara Dolińska
Journal:  Molecules       Date:  2020-05-07       Impact factor: 4.411

7.  Human Immunodeficiency Virus-Associated Exosomes Promote Kaposi's Sarcoma-Associated Herpesvirus Infection via the Epidermal Growth Factor Receptor.

Authors:  Lechuang Chen; Zhimin Feng; Guoxiang Yuan; Corey C Emerson; Phoebe L Stewart; Fengchun Ye; Ge Jin
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

8.  Data Mining Identifies Six Proteins that Can Act as Prognostic Markers for Head and Neck Squamous Cell Carcinoma.

Authors:  Zeng-Hong Wu; Qing Cheng
Journal:  Cell Transplant       Date:  2020 Jan-Dec       Impact factor: 4.064

9.  Exosomes derived from HIV-1-infected cells promote growth and progression of cancer via HIV TAR RNA.

Authors:  Lechuang Chen; Zhimin Feng; Hong Yue; Douglas Bazdar; Uri Mbonye; Chad Zender; Clifford V Harding; Leslie Bruggeman; Jonathan Karn; Scott F Sieg; Bingcheng Wang; Ge Jin
Journal:  Nat Commun       Date:  2018-11-02       Impact factor: 14.919

Review 10.  Pharmacological Benefits and Risk of Using Hormones in Organ Perfusion and Preservation Solutions in the Aspect of Minimizing Hepatic Ischemia-Reperfusion Injury during Storage.

Authors:  Aneta Ostróżka-Cieślik; Barbara Dolińska
Journal:  Biomed Res Int       Date:  2019-11-11       Impact factor: 3.411
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.